Cargando…

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

INTRODUCTION: Dapagliflozin is a selective sodium glucose co-transporter 2 inhibitor that improves glycemic control and reduces body weight and systolic blood pressure in patients with type 2 diabetes mellitus (T2DM). Dapagliflozin is effective and well tolerated over 12–24 weeks in Japanese patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaku, Kohei, Maegawa, Hiroshi, Tanizawa, Yukio, Kiyosue, Arihiro, Ide, Yumiko, Tokudome, Takuto, Hoshino, Yuji, Yang, Jisin, Langkilde, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269643/ https://www.ncbi.nlm.nih.gov/pubmed/25341477 http://dx.doi.org/10.1007/s13300-014-0086-7

Ejemplares similares

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
por: Kaku, Kohei, et al.
Publicado: (2015)

Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early‐stage type 2 diabetes
por: Hirukawa, Hidenori, et al.
Publicado: (2018)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial
por: Fukushima, Yasushi, et al.
Publicado: (2012)

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial
por: Araki, Eiichi, et al.
Publicado: (2019)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
por: Kaku, Kohei, et al.
Publicado: (2014)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
por: Kaku, Kohei, et al.
Publicado: (2014)

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial
por: Nomura, Akihiro, et al.
Publicado: (2019)

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

Spinal intraosseous arteriovenous fistulas with perimedullary drainage associated with vertebral compression fracture: illustrative case
por: Baba, Hiroshi, et al.
Publicado: (2022)

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
por: Seino, Yutaka, et al.
Publicado: (2012)

A Single Nucleotide Polymorphism within DUSP9 Is Associated with Susceptibility to Type 2 Diabetes in a Japanese Population
por: Fukuda, Hisashi, et al.
Publicado: (2012)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

Replication Study for the Association of 9 East Asian GWAS-Derived Loci with Susceptibility to Type 2 Diabetes in a Japanese Population
por: Sakai, Kensuke, et al.
Publicado: (2013)

Replication study for the association of rs391300 in SRR and rs17584499 in PTPRD with susceptibility to type 2 diabetes in a Japanese population
por: Imamura, Minako, et al.
Publicado: (2012)

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
por: Imamura, Akira, et al.
Publicado: (2013)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak, Jan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial
por: Seino, Yutaka, et al.
Publicado: (2011)

Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry
por: Minatsuki, Shun, et al.
Publicado: (2021)

Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
por: Ito, Daisuke, et al.
Publicado: (2021)

Replication Study in a Japanese Population of Six Susceptibility Loci for Type 2 Diabetes Originally Identified by a Transethnic Meta-Analysis of Genome-Wide Association Studies
por: Matsuba, Ren, et al.
Publicado: (2016)

Association of New Loci Identified in European Genome-Wide Association Studies with Susceptibility to Type 2 Diabetes in the Japanese
por: Ohshige, Toshihiko, et al.
Publicado: (2011)

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
por: Feng, Miao, et al.
Publicado: (2019)

Replication Study in a Japanese Population to Evaluate the Association between 10 SNP Loci, Identified in European Genome-Wide Association Studies, and Type 2 Diabetes
por: Matsuba, Ren, et al.
Publicado: (2015)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

Oral glucose‐stimulated serum C‐peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment
por: Araki, Hisazumi, et al.
Publicado: (2013)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o9kfkood70ieij8ltl6b2kcmb9